Cannara Biotech Inc. (TSX:LOVE)
Canada · Delayed Price · Currency is CAD 2.080
-0.060 (-2.80%)
Oct 9, 2026, 3:59 PM EST
Cannara Biotech Ratios and Metrics
Market cap in millions CAD. Fiscal year is September - August.
Millions CAD. Fiscal year is Sep - Aug.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
| 205 | 165 | 61 | 90 | 118 | 149 | |
Market Cap Growth | 22.25% | 168.86% | -32.29% | -23.64% | -20.54% | 112.60% |
Enterprise Value | 221 | 198 | 105 | 131 | 146 | 160 |
Last Close Price | 2.08 | 1.80 | 0.68 | 1.00 | 1.35 | 1.70 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
PE Ratio | 18.92 | 12.59 | 9.51 | 13.02 | 51.35 | - |
Forward PE | 11.40 | 12.41 | - | - | - | - |
PS Ratio | 1.75 | 1.54 | 0.75 | 1.58 | 3.30 | 8.75 |
PB Ratio | 1.63 | 1.61 | 0.70 | 1.13 | 1.77 | 2.32 |
P/TBV Ratio | 1.67 | 1.61 | 0.70 | 1.13 | 1.77 | 2.32 |
P/FCF Ratio | 36.06 | 12.05 | 19.05 | - | - | - |
P/OCF Ratio | 10.57 | 8.22 | 5.73 | 15.29 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
EV/Sales Ratio | 1.88 | 1.84 | 1.28 | 2.29 | 4.07 | 9.40 |
EV/EBITDA Ratio | 8.82 | 7.04 | 7.62 | 7.92 | 16.91 | 58.11 |
EV/EBIT Ratio | 12.09 | 9.13 | 13.69 | 11.17 | 30.25 | 3041.19 |
EV/FCF Ratio | 38.73 | 14.47 | 32.55 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Debt / Equity Ratio | 0.29 | 0.41 | 0.55 | 0.57 | 0.73 | 0.33 |
Debt / EBITDA Ratio | 1.48 | 1.47 | 3.45 | 2.75 | 5.54 | 7.15 |
Debt / FCF Ratio | 6.50 | 3.05 | 15.04 | - | - | - |
Net Debt / Equity Ratio | 0.12 | 0.27 | 0.47 | 0.52 | 0.54 | 0.20 |
Net Debt / EBITDA Ratio | 0.61 | 0.97 | 3.04 | 2.51 | 4.21 | 4.63 |
Net Debt / FCF Ratio | 2.67 | 1.99 | 12.98 | -10.46 | -1.68 | -0.38 |
Asset Turnover | 0.64 | 0.66 | 0.55 | 0.43 | 0.33 | 0.23 |
Inventory Turnover | 1.29 | 1.32 | 1.41 | 1.14 | 1.40 | 1.39 |
Quick Ratio | 1.24 | 0.83 | 0.73 | 0.70 | 1.75 | 1.63 |
Current Ratio | 3.00 | 2.40 | 2.50 | 2.44 | 3.46 | 2.82 |
Return on Equity (ROE) | 9.68% | 13.75% | 7.68% | 9.48% | 3.52% | -2.98% |
Return on Assets (ROA) | 6.26% | 8.37% | 3.23% | 5.48% | 2.77% | 0.04% |
Return on Invested Capital (ROIC) | 8.90% | 12.08% | 6.09% | 10.45% | 5.36% | 0.09% |
Return on Capital Employed (ROCE) | 11.30% | 16.10% | 6.00% | 9.70% | 4.20% | 0.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 9, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Earnings Yield | 5.29% | 7.95% | 10.52% | 7.68% | 1.95% | -1.03% |
FCF Yield | 2.77% | 8.30% | 5.25% | -4.39% | -18.20% | -22.26% |
Buyback Yield / Dilution | -5.67% | -1.08% | -1.83% | -2.16% | -14.80% | -7.26% |